Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration

• Status: Unknown status
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asociación para Evitar la Ceguera en México
• Treatments: Bevacizumab; Verteporfin

Criteria

Inclusion Criteria:

55 years old neovascular Age related acular degeneration subfoveolar neovascular membrane best corrected visual acuity better than 20/200 snellen (1.0 logMAR)

Exclusion Criteria:

• Previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease